Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Jan
7
2022
FDA Releases Guidance for Digital Health Tech Used in Clinical Investigations Sheppard, Mullin, Richter & Hampton LLP
Jun
19
2014
Supreme Court Rules Compliance with Food and Drug Administration (FDA) Labeling Guidelines Does Not Bar Lanham Act False Advertising Suits – POM Wonderful v. Coca-Cola Co. Sheppard, Mullin, Richter & Hampton LLP
Dec
27
2014
J.M. Smucker Company Gets Out of a Jam in Food Labelling Case - Caldera v. The J.M. Smucker Co. Sheppard, Mullin, Richter & Hampton LLP
Aug
19
2019
Spate of Recent False Advertising Class Actions Take On Animal Treatment Label Claims Sheppard, Mullin, Richter & Hampton LLP
Dec
2
2022
Proposal to Overhaul Privacy Law Governing Substance Use Disorder Treatment Records Sheppard, Mullin, Richter & Hampton LLP
Dec
20
2022
Comment Period for “Healthy” Regulations Extended; But Consumer Class Actions Targeting “Health Halos” May Continue Sheppard, Mullin, Richter & Hampton LLP
May
25
2023
Florida Bans Offshoring of Certain Patient Information Sheppard, Mullin, Richter & Hampton LLP
Apr
5
2016
Challenge to California Ordinance Prohibiting Mobile Medical Marijuana Dispensaries Goes Up in Smoke Sheppard, Mullin, Richter & Hampton LLP
Jun
22
2023
Connecticut Governor Signs Health Care Legislation to Reduce Costs and Increase Competition Sheppard, Mullin, Richter & Hampton LLP
Jan
31
2024
OIG Permits Medical Device Manufacturer’s Cost-Sharing Subsidies for Medicare Beneficiaries in Clinical Trial Sheppard, Mullin, Richter & Hampton LLP
Feb
10
2021
Federal Circuit Agrees to Reconsider Ruling in GSK v. Teva Drug Patent Case Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2009
OTC Drug and Dietary Supplement Labeling: Adverse Event Reporting Information Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2018
340B Drug Pricing Program Litigation Update: American Hospital Association, Et Al. v. Azar Sheppard, Mullin, Richter & Hampton LLP
Dec
30
2021
San Francisco Passes Measure Requiring Sick Leave for Domestic Workers – “First of Its Kind” Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2014
Review – U.S. Patent and Trademark Office Subject Matter Eligibility Guidelines Sheppard, Mullin, Richter & Hampton LLP
May
17
2022
California Cannabis Farmers May Finally Get Some Relief Sheppard, Mullin, Richter & Hampton LLP
Dec
5
2014
Now That That’s Settled: The Status of Class Action Settlements in the Seventh Circuit after Pella, Radioshack and NBTY Sheppard, Mullin, Richter & Hampton LLP
Jul
26
2022
New Litigation Continues to Challenge the Social Equity and Scoring Process of the Illinois Cannabis Regulation And Tax Act Sheppard, Mullin, Richter & Hampton LLP
Mar
17
2015
California Federal Court Finds that Class Action Plaintiffs’ False Advertising Claims are Stripped Bayer Based on Federal Preemption Sheppard, Mullin, Richter & Hampton LLP
Nov
28
2022
Federal Judge in NY Issues Preliminary Injunction to Block Retail Cannabis Licenses on Constitutional Grounds Sheppard, Mullin, Richter & Hampton LLP
Aug
28
2015
What’s in a Name? That Which We Call a Biological Product… Sheppard, Mullin, Richter & Hampton LLP
Feb
25
2023
No Surprises Act Update: Certified IDR Entities to Resume Payment Determinations for Services Furnished Before October 25, 2022 Sheppard, Mullin, Richter & Hampton LLP
Jan
19
2016
Extending Patentable Life of 3D Printers: Lesson From Pharmaceutical Industry Sheppard, Mullin, Richter & Hampton LLP
Apr
11
2023
“Dietary Guidance Statements” in Food Labeling: What You Need to Know About FDA’s Latest Draft Guidance for the Food Industry Sheppard, Mullin, Richter & Hampton LLP
Jan
22
2020
New Jersey Court Commands Cannabis Reimbursement in Workers’ Compensation Dispute Sheppard, Mullin, Richter & Hampton LLP
Jul
24
2023
Regulators Send Warning Letter to Hospitals and Telehealth Providers About Tracking Technology Use Sheppard, Mullin, Richter & Hampton LLP
Apr
7
2020
Nota Bene Episode 73: “Quarantine and Chill”: Will COVID-19 Impact the Cannabis Industry? with Whitney Hodges Sheppard, Mullin, Richter & Hampton LLP
Oct
18
2023
FDA’s Proposed Rule on LDT Regulation and the Debate over Agency Deference Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins